Clough Capital Partners’s bluebird bio BLUE Stock Holding History

Clough Capital Partners’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,687	Closed	-$3.19M	–	150
2018 Q3	$3.19M	Sell	1,687 -1,011	-37%	-$2.09M	0.3%	71
2018 Q2	$5.49M	Buy	2,698 +2,179	+420%	+$4.97M	0.49%	60
2018 Q1	$1.15M	Buy	519 +201	+63%	+$511K	0.11%	90
2017 Q4	$734K	Sell	318 -83	-21%	-$169K	0.06%	94
2017 Q3	$714K	Buy	401 +247	+160%	+$345K	0.05%	92
2017 Q2	$210K	Sell	154 -394	-72%	-$475K	0.01%	123
2017 Q1	$645K	Sell	548 -147	-21%	-$150K	0.04%	116
2016 Q4	$555K	Buy	+695	New	+$552K	0.04%	142

Other funds holding BLUE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Clough Capital Partners's BLUE Position: Q4 2018 in Review

Clough Capital Partners sold out of bluebird bio (BLUE) in Q4 2018, closing a stake of 1,687 shares — an estimated $3.19M sold.

Clough Capital Partners first reported a position in BLUE in Q4 2016 and held it in 8 quarters. The position peaked at $5.49M in Q2 2018. 251 funds tracked by Wall St. Rank hold BLUE as of Q4 2018.

Clough Capital Partners reported no remaining bluebird bio position as of Q4 2018 after selling out during the quarter.
Clough Capital Partners sold 1,687 bluebird bio shares in Q4 2018, an estimated $3.19M.
Clough Capital Partners first reported a position in bluebird bio in Q4 2016 and held it in 8 quarters.
Clough Capital Partners's bluebird bio position peaked at $5.49M in Q2 2018.
251 funds tracked by Wall St. Rank held bluebird bio as of Q4 2018.

Based on Clough Capital Partners's 13F filing for Q4 2018, filed 14 Feb 2019.